Regional Analysis
The Recombinant DNA Technology Market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas region holds the largest market share of the global recombinant DNA technology market due to the presence of effective regulations pertaining to the approval of recombinant therapeutics and other Genetically Modified (GM) products. F. Hoffmann-La Roche Ltd, Amgen Inc., Novartis AG, Monsanto Company, Eli Lilly and Company, and Biogen Inc. are some of the major companies operating in this space that are responsible for the growth of the Americas recombinant DNA technology market.
Furthermore, there is an increasing need to improve the recombinant proteins production capacity by several folds in Europe. The increase in demand for effective therapeutics for the treatment of diseases and technological advancements in this sector are anticipated to drive the growth of the European recombinant DNA technology market.
Asia Pacific is expected to emerge as the fastest growing regional market for the global recombinant DNA technology market. The increasing awareness about the growing genetic diseases and disorders, developing healthcare infrastructure, increasing spending on healthcare, increasing government initiatives to improve public health, and advances in medical fields are driving the market growth.
The Middle East and Africa is expected to experience a limited growth due to less demand for genetic testing. The Middle East is growing significantly as compared to the African recombinant DNA technology market owing to the increase in aging population, innovations in genetic testing, and increase in the number of chronic disease cases.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/5845
Key Players
Some of the key players in the global recombinant DNA technology market are F. Hoffmann-La Roche Ltd (Switzerland), Profacgen (U.S.), Amgen Inc. (U.S.), Novartis AG (Switzerland), Genscript Biotech (U.S.), Pfizer Inc. (U.S.), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Merck & Co., Inc. (U.S.), Biogen Inc. (U.S.), Biocon Limited (India), GlaxoSmithKline plc (UK), New England Biolabs (U.S.), Cibus (U.S.), Monsanto Company (U.S.), Horizon Discovery Group PLC (U.S.), Boehringer Ingelheim (Germany), and others.
Segmentation
The global recombinant DNA technology market is segmented on the basis of product, component, application, and end-user.
On the basis of product, the global recombinant DNA technology market is segmented into medical, non-medical, and others. The medical segment is divided into therapeutic agent, human protein, and vaccines. The non-medical segment is divided into biotech crops, specialty chemicals, and others.
On the basis of component, the global recombinant DNA technology market is segmented into expression system, cloning vector, and others. The expression system segment is divided into mammalian, bacteria, yeast, baculovirus/insect, and others. The cloning vector segment is divided into plasmid, phage, cosmid, Bacterial Artificial Chromosome (BAC), Yeast Artificial Chromosome (YAC), and Human Artificial Chromosome (HAC).
On the basis of application, the global recombinant DNA technology market is segmented into food and agriculture, health and disease, environment, and others.
On the basis of end-user, the global recombinant DNA technology market is segmented into biotechnology companies, academic and government research institutes, pharmaceuticals, and others.
Access Report Details @ https://www.marketresearchfuture.com/reports/recombinant-dna-technology-market-5845
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact:
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America
